RESEARCH TRIANGLE PARK, N.C. – June 8, 2011 – Quintiles Transnational Corp. (the “Company”), today announced that it has completed new $2.2 billion credit facility arrangements. The new credit facilities include a $225 million first lien revolving credit facility due in 2016 and a $2.0 billion first lien term loan B due in 2018.
Proceeds from these borrowings were used to refinance approximately $1.7 billion of existing debt, including to pay the purchase price for Notes accepted in the tender offer described below and to redeem the Notes remaining outstanding following completion of the tender offer. Additional proceeds will be employed for a variety of purposes.
The previously announced cash tender offer and consent solicitation relating to the outstanding $525 million aggregate principal amount 9.50% senior notes due December 2014 (the “Notes”) of Quintiles Transnational Holdings Inc., the Company’s parent company (“Holdings”), expired at midnight on Tuesday, June 7, 2011. Holdings has waived the minimum tender and supplemental indenture conditions to the tender offer and consent solicitation and, on June 8, 2011, accepted for purchase all of the Notes validly tendered. Settlement for Notes accepted for purchase in the tender offer and consent solicitation occurred today.
Additionally, Holdings has issued a notice stating that all of the Notes that remain outstanding after completion of the tender offer will be redeemed on July 8, 2011. This press release does not constitute a notice of redemption. A notice of redemption is made only by a formal written Notice of Redemption to the registered holders of the Notes.
Wells Fargo Securities, LLC acted as the dealer manager and solicitation agent in connection with the tender offer. Global Bondholder Services Corporation served as the tender agent and information agent for the tender offer.
This press release does not constitute an offer to buy, the solicitation of an offer to sell or the solicitation of consents with respect to the Notes. The full terms of the tender offer and consent solicitation are set forth in the Offer to Purchase and Consent Solicitation Statement dated May 10, 2011, and in the Letter of Transmittal.
Quintiles is the only fully integrated biopharmaceutical services company offering clinical, commercial, consulting and capital solutions worldwide. The Quintiles network of more than 20,000 engaged professionals in 60 countries around the globe works with an unwavering commitment to patients, safety and ethics. Quintiles helps biopharmaceutical companies navigate risk and seize opportunities in an environment where change is constant. For more information, please visit www.quintiles.com.